Prosensa and GlaxoSmithKline expand Duchenne dystrophy alliance
Leiden - Prosensa NV and British drugmaker GlaxoSmithKline have expanded their cooperation concerning RNA-modulating drugs against Duchenne muscular dystrophy (DMD). Two programmes, covering 4 drug new drug candidates for specific patient subpopulations, have been added to the existing collaboration in DMD. According to the terms of the agreement, GSK has paid two upfront fees and will add milestones dependant on research progress. Within the new programmes, Prosensa and GSK will focus on the skipping of four exons (exon 45, 52, 53, and 55), in addition to their existing programmes that target skipping of exon 51 and 44 (PRO051/GSK2402968 and PRO044). GSK has an option to select two of these additional four compounds for later-stage development and commercialization. Prosensa will retain certain limited European commercialisation rights alongside GSK for the two compounds selected by GSK. For the two compounds not selected by GSK, Prosensa will retain full commercialization rights.